Supportive care for patients with early breast cancer

Abstract

Breast cancer treatment currently requires the joint efforts of a multidisciplinary team to effectively combine chemotherapy, hormone therapy, biological agents, surgery and radiation therapy when needed. To develop such a treatment plan, it is important to know the benefits as well as the potential toxic effects of each therapy. Thus, many patients with early breast cancer complain of collateral adverse events such as fatigue, nausea, vomiting, loss of libido, hot flashes, night sweats or neuropathy due to the complex therapies they are receiving. To date, the treatment of such symptoms is an important issue that greatly affects the quality of life of these patients. In this review, we report the content of a multi-expert meeting where the incidence of and medical approach to some of the most common adverse events encountered during the treatment of patients with early breast cancer were analysed.

Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease

“…In fact, the recognition and prospective identification of salient individual differences provides the basis for “personalized medicine", which is being implemented in the clinic at an accelerated pace owing for a variety of scientific and technological advances 54, 55. And fourth, the frequency with which symptoms are reported depends greatly on the expectations and communications among providers, investigators, and patients 56, 57. No studies appear to have been conducted wherein validated survey tools (e.g., the Ocular Surface Disease Index (OSDI)58) have been used for assessing ocular-surface discomfort stemming from chemotherapy, for example.…”

Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer

“…4 Therefore, more and more supportive measures are validated in oncology. [5][6][7] This article was published in the following Dove Press journal: Breast Cancer: Targets and Therapy 1 August 2014 Number of times this article has been viewed submit your manuscript | www.dovepress.com…”

Estudo prospectivo, duplo-cego e randomizado, para avaliar a eficácia e a tolerabilidade do suplemento nutricional "TK3" na redução da toxicidade apresentada por pacientes em quimioterapia para diferentes tipos de câncer

“…A redução dos efeitos colaterais de quimioterápicos contribui para a melhoria da qualidade de vida do paciente e favorece a sua adesão ao tratamento, aumentando as chances de sucesso do tratamento (García-Estévez et al, 2010). A doxorrubicina é um antibiótico do grupo das antraciclinas, isolado do…”